Lori A. Leslie, MD

Articles

Dr. Leslie on the Development of CAR T-Cell Therapy in DLBCL and MCL

September 28th 2020

Lori A. Leslie, MD, discusses developments in CAR T-cell therapy in diffuse large B-cell lymphoma and mantle cell lymphoma.

Dr. Leslie on Sequencing Zanubrutinib in MCL

September 23rd 2020

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses sequencing strategies with zanubrutinib in mantle cell lymphoma.

Dr. Leslie on the Need for Clinical Trials to Address Unmet Needs in MCL

September 16th 2020

Lori A. Leslie, MD, discusses the importance of clinical trials in finding novel, up-front therapy options for patients with mantle cell lymphoma.

Dr. Leslie on the Role of Zanubrutinib in MCL

September 14th 2020

Lori A. Leslie, MD, discusses the role of zanubrutinib in mantle cell lymphoma.

Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies

September 9th 2020

Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.

Dr. Leslie on Emerging Therapies in MCL

September 3rd 2020

Lori A. Leslie, MD, lymphoma attending, discusses emerging therapies in mantle cell lymphoma.

Dr. Leslie on Frontline Treatment Options in Follicular Lymphoma

August 24th 2020

Lori A. Leslie, MD, lymphoma attending, discusses frontline treatment options in follicular lymphoma.

Dr. Leslie on Phase 1b Trial of Tazemetostat Plus Lenalidomide/Rituximab in Follicular Lymphoma

August 22nd 2020

Lori A. Leslie, MD, discusses a phase 1b study with tazemetostat plus lenalidomide and rituximab in patients with follicular lymphoma.

Dr. Leslie on Current Treatment Options for Relapsed/Refractory MCL

July 23rd 2020

Lori A. Leslie, MD, discusses current treatment options for patients with relapsed/refractory mantle cell lymphoma.

Dr. Leslie on the Encouraging Evolving Treatment Landscape in MCL

July 21st 2020

Lori A. Leslie, MD, discusses the encouraging evolving treatment landscape in mantle cell lymphoma.

x